GUILFORD, Conn., July 29, 2020 — InveniAI® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, is pleased to announce a strategic collaboration with GlaxoSmithKline Consumer Healthcare, a science-led global healthcare company with a mission to help people to do more, feel better and live longer, and one of the world's leading over-the-counter (OTC) medicines companies.
Three-year strategic collaboration to leverage InveniAI's AI- and ML-powered Platform, AlphaMeld® after a successful proof-of-value collaboration. AlphaMeld® will capture consumer-specific innovation for both internal and external R&D.
GlaxoSmithKline Consumer Healthcare will leverage AlphaMeld®, an AI and ML platform that empowers internal teams to efficiently evaluate and navigate emerging innovation spanning the Company's key focus areas. The three-year collaboration will grant full access to InveniAI's AI Innovation Lab and an internal team of cross-functional experts to facilitate accelerated access to innovation.
Michael Keane, Director, Search and Evaluation, GSK Consumer Healthcare, said, "At GSK Consumer Healthcare, patients and consumers are central to what we do, and it is their needs that drive innovation and product development at GSK. AI and ML have helped create efficiencies that shave 4-5 years off the innovation cycle as well as eliminate human biases in identifying innovation."
Aman Kant, InveniAI's Chief Business Officer, said, "We are excited about this unique collaboration that will help GSK to utilize the power of an AI-driven platform to identify and develop innovative life-changing healthcare products for their consumers. This customized platform delivers tremendous business value by not only rapidly assimilating large volumes of disparate data sets to facilitate a first-mover advantage, but also releases expert human resources at GSK to focus on higher-value tasks."